US Bancorp DE Acquires 1,616 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

US Bancorp DE boosted its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLOGet Rating) by 41.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,474 shares of the company’s stock after purchasing an additional 1,616 shares during the quarter. US Bancorp DE’s holdings in Allogene Therapeutics were worth $63,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Gratus Capital LLC raised its holdings in Allogene Therapeutics by 5.7% during the 2nd quarter. Gratus Capital LLC now owns 213,986 shares of the company’s stock worth $2,439,000 after purchasing an additional 11,546 shares during the last quarter. Arizona State Retirement System raised its holdings in Allogene Therapeutics by 9.6% during the 2nd quarter. Arizona State Retirement System now owns 23,212 shares of the company’s stock worth $265,000 after purchasing an additional 2,024 shares during the last quarter. Bourgeon Capital Management LLC raised its holdings in Allogene Therapeutics by 20.8% during the 2nd quarter. Bourgeon Capital Management LLC now owns 32,000 shares of the company’s stock worth $365,000 after purchasing an additional 5,500 shares during the last quarter. Navalign LLC raised its holdings in Allogene Therapeutics by 1.5% during the 2nd quarter. Navalign LLC now owns 75,365 shares of the company’s stock worth $859,000 after purchasing an additional 1,094 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Allogene Therapeutics during the 2nd quarter worth about $1,250,000. 84.81% of the stock is owned by institutional investors.

Allogene Therapeutics Stock Up 8.9 %

NASDAQ:ALLO opened at $9.54 on Friday. Allogene Therapeutics, Inc. has a twelve month low of $6.43 and a twelve month high of $19.62. The business has a 50 day moving average price of $11.34 and a two-hundred day moving average price of $11.33. The company has a market cap of $1.38 billion, a P/E ratio of -4.34 and a beta of 0.59.

Allogene Therapeutics (NASDAQ:ALLOGet Rating) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.04. Allogene Therapeutics had a negative return on equity of 37.74% and a negative net margin of 126,580.16%. During the same quarter in the prior year, the company posted ($0.57) earnings per share. As a group, analysts anticipate that Allogene Therapeutics, Inc. will post -2.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ALLO shares. Truist Financial decreased their target price on Allogene Therapeutics to $29.00 in a research report on Tuesday, August 23rd. The Goldman Sachs Group upgraded Allogene Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $9.00 to $32.00 in a research report on Friday, July 15th. Raymond James lowered Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 10th. B. Riley decreased their target price on Allogene Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, September 22nd. Finally, Oppenheimer decreased their price objective on Allogene Therapeutics to $32.00 in a research report on Thursday, October 13th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $27.10.

Allogene Therapeutics Profile

(Get Rating)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

Featured Stories

Institutional Ownership by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.